Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke
Status:
Terminated
Trial end date:
2015-06-11
Target enrollment:
Participant gender:
Summary
Randomized controlled clinical trial to estimate overall treatment benefit (improvement in
disability) among stroke patients treated with rt-PA who are randomized to also receive
either low-dose Argatroban, high-dose Argatroban or neither.
Phase:
Phase 2
Details
Lead Sponsor:
Andrew D. Barreto, MD
Collaborator:
The University of Texas Health Science Center, Houston